NVO Jan 2025 280.000 call
| Previous close | 5.80 |
| Open | 5.80 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 280.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.80 - 5.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 330 |
Barrons.comNew Weight-Loss Drugs and Devices Are Coming This Week
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.
Investor's Business DailyTop Weight-Loss Rivals Share This Risk After Eye-Popping Runs
Popular weight-loss drugs have boosted Novo Nordisk and Eli Lilly. After huge gains, the drugmakers' stocks now face this risk.
Globe NewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat
